---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-038532"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:21:32.694843+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics enters exclusive license with Factor Bioscience for cancer, autoimmune, rare disease tech

## Summary
- Exclusive license in cancer, autoimmune disorders, and rare diseases; replaces Nov 2023 and prior Exacis licenses.
- Pays Factor $208,333/month for first 12 months and $50,000/month for first 9 months for patent costs.
- Initial term one year, auto-renews; Eterna may terminate for any reason with 90 days notice.
- Factor to provide services and materials to facilitate development and scale-up at third-party facilities.

## SEC filing metadata
- accession: 0001493152-24-038532
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315224038532/0001493152-24-038532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315224038532/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-038532
- JSON: https://secwatch.observer/filing/0001493152-24-038532.json
- Plain text: https://secwatch.observer/filing/0001493152-24-038532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.